0000000000480838

AUTHOR

Thilo Gambichler

showing 2 related works from this author

S2k guidelines for Merkel cell carcinoma (MCC, neuroendocrine carcinoma of the skin) – update 2018

2019

Merkel cell carcinoma (MCC, ICD-O M8247 / 3) is a rare malignant primary skin tumor with epithelial and neuroendocrine differentiation. The neoplastic cells share many morphological, immunohistochemical and ultrastructural characteristics with Merkel cells of the skin. The diagnosis of MCC is rarely made on clinical grounds. Histological and immunohistochemical studies are usually required to confirm the clinical suspicion. Given the frequent occurrence of occult lymph node metastasis, sentinel lymph node biopsy should be performed once distant metastasis has been ruled out by cross-sectional imaging. Primary tumors without evidence of organ metastases are treated with complete surgical exc…

medicine.medical_specialtySkin Neoplasmsmedicine.medical_treatmentSentinel lymph nodeMedizinAntineoplastic AgentsDermatologyNeuroendocrine differentiation030207 dermatology & venereal diseases03 medical and health sciences0302 clinical medicineBiopsyCarcinomaHumansMedicineNeoadjuvant therapyAgedNeoplasm Stagingmedicine.diagnostic_testbusiness.industryMerkel cell carcinomaPrognosismedicine.diseaseNeoadjuvant TherapyCarcinoma Merkel CellRadiation therapymedicine.anatomical_structureLymphatic MetastasisImmunotherapyRadiologyNeoplasm Recurrence LocalCognition DisordersbusinessMerkel cell
researchProduct

Immune checkpoint inhibition therapy for advanced skin cancer in patients with concomitant hematological malignancy: a retrospective multicenter DeCO…

2020

BackgroundSkin cancers are known for their strong immunogenicity, which may contribute to a high treatment efficacy of immune checkpoint inhibition (ICI). However, a considerable proportion of patients with skin cancer is immuno-compromised by concomitant diseases. Due to their previous exclusion from clinical trials, the ICI treatment efficacy is poorly investigated in these patients. The present study analyzed the ICI treatment outcome in advanced patients with skin cancer with a concomitant hematological malignancy.MethodsThis retrospective multicenter study included patients who were treated with ICI for locally advanced or metastatic melanoma (MM), cutaneous squamous cell carcinoma (cS…

0301 basic medicineOncologyMaleCancer Researchmedicine.medical_specialtySkin Neoplasms2435medicine.medical_treatmentChronic lymphocytic leukemiaImmunologyMedizin03 medical and health sciences0302 clinical medicineInternal medicinemedicinemelanomaImmunology and AllergyHumans1506Immune Checkpoint InhibitorsRC254-282AgedRetrospective StudiesPharmacologyClinical/Translational Cancer ImmunotherapyMerkel cell carcinomabusiness.industryMelanomaNeoplasms. Tumors. Oncology. Including cancer and carcinogensImmunotherapyMiddle Agedmedicine.diseaseSurvival AnalysisLymphoma030104 developmental biologyOncology030220 oncology & carcinogenesisConcomitantHematologic NeoplasmsMolecular MedicineFemaleImmunotherapySkin cancerbusinessProgressive diseaseJournal for Immunotherapy of Cancer
researchProduct